Glasgow, Leeds, London, Sheffield

Full title: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after failure of Imatinib

Age: 18+

Phase: 3

This trial looks at the effectiveness of the drug DCC-2618 compared to sunitinib in GIST patients who progressed on or had bad side effects to the drug imatinib. Patients will be randomly divided into two groups. One group will be given the drug DCC-2618 and the other group will be given sunitinib.